Clinical Trial Update: Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating maintenance zanzalintinib plus durvalumab in advanced hepatocellular carcinoma; the study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: Amit Mahipal | Conditions: Hepatocellular Carcinoma, Liver Cancer | Phase 2 | Status: NOT_YET_RECRUITING